i3 Health

12/13/2025

At , multiple trials in the early-stage, metastatic, and + settings delivered data that may change practice. Afterwards, Jasmin Hundal, MD, MS, MPH, sat down to explore the data and the importance of patient‑centered communication.

Watch now: https://www.youtube.com/watch?v=eWrbeNtRe90

12/12/2025

Oral targeted therapies have reshaped first‑line CLL care—but toxicity monitoring, access, and adherence remain critical. Pharmacists are central to selection, safety, and patient education.

Watch on YouTube: https://www.youtube.com/watch?v=apiia5YFQa0&t=2s

Complete the activity and claim your credit today: https://bit.ly/4mN2WgRChronic lymphocytic leukemia (CLL) treatment has evolved with the introduction of ta...

12/12/2025

Meet our Faculty Friday spotlight: Ulka Vaishampayan, MD, FASCO—Professor of Medicine/Oncology and Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center.

She specializes in genitourinary malignancies (prostate, bladder, renal cell carcinoma), with research in translational drug development.

Start her activity here: https://bit.ly/3XA605R

12/11/2025

Expiring soon: Pediatric atopic dermatitis carries a high burden—itch, pain, sleep disruption—and the treatment toolbox has expanded with newer non‑steroidal topicals, biologics, oral JAK inhibitors, and OX40‑pathway agents on the horizon.

Complete now: https://bit.ly/47DWC6T

Peter A. Lio, MD | Northwestern University Feinberg School of Medicine
Linda F. Stein Gold, MD | Henry Ford Health

12/11/2025

"AI doesn’t replace pathologists, but empowers them by improving efficiency and diagnostic precision." - Osama Khan, MD

Read the full interview here: https://bit.ly/44UUKVD

12/10/2025

Did you know? Nearly 90% of adults with type 2 diabetes mellitus (T2DM) are overweight or have obesity, highlighting the critical link between these conditions.

Learn about novel therapies targeting both T2DM and obesity in this activity: https://bit.ly/4bW5PIm

12/10/2025

Your Update: Here’s what’s new this week from i3 Health!

Pembrolizumab–Enfortumab Vedotin-ejfv Combination Approved for Muscle Invasive Bladder Cancer: https://bit.ly/4pWF4ct

Tarlatamab-dlle Approved for Relapsed Extensive-Stage Small Cell Lung Cancer: https://bit.ly/4pxovEo

CAR T in Practice: What Oncologists Need to Know With Ehsan Malek, MD: https://bit.ly/495gvEI

12/09/2025

How do you approach EP‑NECs—rare, aggressive, and heterogeneous—across GEP, GU, and gynecologic sites, and where do targeted therapy, immunotherapy, and radionuclide therapy fit today?

Andrew E. Hendifar, MD | Cedars-Sinai

12/09/2025

Hereditary ATTR amyloidosis is progressive and often misdiagnosed—ATTR‑CM symptoms overlap with common cardiac diseases.

Complete the activity to learn detection and management strategies: https://bit.ly/4ntAv8Z

Mathew S. Maurer, MD | Columbia University Irving Medical Center

12/06/2025

Clinicians see the arc—diagnosis, staging, treatment—but patients live the burden: 100+ appointments, logistics, fear, and cognitive load. In this interview, Waqas Haque, MD, MPH, talks with survivor/founder Samira Daswani (Manta Cares) about redesigning cancer care around the patient journey.

Read more here: https://bit.ly/48q3PXu

12/05/2025

Learn how to slow ALS progression and optimize quality of life with Dr. Richard S. Bedlack, a leading expert from Duke University. Discover cutting-edge insights and research. Click the link to complete the full activity and claim credit! https://bit.ly/3J4fTVM

12/04/2025

Biomarkers are transforming esophagogastric cancer care! Join Dr. Yelena Janjigian from Memorial Sloan Kettering as she explores HER2, PD-L1, MSI-H, and other key biomarkers guiding treatment decisions. Click the link to complete the full activity, "Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care," and claim credit!

https://bit.ly/41rP57F